CM313 exhibits broad but heterogeneous activity against CD38+ cells, including MM, Burkitt’s lymphoma, diffuse large B lymphoma, acute B lymphoid leukemia and acute T lymphoid leukemia cell lines. This evidence concerns the gene CD38 and Miyoshi myopathy.